Skip to content

503B Outsourcing Facility Services in New York

FarmaKeio's 503B outsourcing facility is designed to bridge the gap between traditional pharmacy compounding and large-scale pharmaceutical manufacturing. We provide New York hospitals, surgical centers, and clinical institutions with a dependable supply of sterile compounded medications prepared under the highest regulatory standards.

Related Pages

What is 503B Outsourcing?

Established under the Drug Quality and Security Act, Section 503B outsourcing facilities are authorized to produce compounded medications for "office use" without requiring patient-specific prescriptions. Unlike traditional 503A pharmacies that focus on individualized, patient-specific dosing, 503B facilities operate at a greater scale to support the clinical workflows and institutional needs of healthcare providers across New York and beyond.

Key Features of the 503B Framework for New York Providers Include:

  • FDA Oversight: 503B facilities must register with the FDA and are subject to regular federal inspections, giving New York institutions confidence in every preparation.
  • CGMP Compliance: Operations must strictly adhere to current Good Manufacturing Practice (CGMP) requirements, ensuring pharmaceutical-grade quality for New York clinical settings.
  • Office-Use Supply: Facilities can produce batches of medications for New York hospitals, surgical centers, and clinics to maintain as ready-to-use inventory.

Why New York Providers Partner with a 503B Facility

For hospitals and large clinical practices throughout New York, managing patient volume and procedural workflows requires absolute medication consistency and supply continuity. Partnering with FarmaKeio helps New York healthcare providers reduce the operational burden of in-house compounding while increasing confidence in preparation standards.

Our 503B Capabilities Support New York Practices Through:

  • Reliable Supply to New York: Access to sterile compounded medications prepared at scale to ensure clinical availability for New York institutions.
  • Workflow Efficiency: Prepared inventory that is ready for immediate clinical or procedural use, streamlining operations in New York facilities.
  • Quality Assurance: Quality systems aligned with pharmaceutical manufacturing standards, including validated protocols and controlled processes trusted by New York providers.

Specialized Focus: Sterile Hormone Pellet Therapy for New York Clinics

FarmaKeio's outsourcing facility maintains a dedicated specialization in sterile hormone pellet production. Using proprietary preparation methods and advanced pellet techniques, we provide practitioners across New York with highly consistent and accurate formulations for their treatment strategies.

503A & 503B: A Complementary Approach for New York Providers

At FarmaKeio, we believe these two pathways work best when they work together. While our 503A operations focus on individualized, patient-specific therapies tailored to unique needs, our 503B facility provides the scalable solutions necessary for broader clinical use in New York. This dual approach ensures your New York practice has the flexibility to provide both customized care and maintain a reliable institutional supply.

Ready to streamline your New York clinical supply?

FarmaKeio's 503B outsourcing facility delivers the scale, consistency, and regulatory rigor that modern healthcare institutions in New York demand. Operating under FDA oversight and strict CGMP standards, we provide hospitals, surgical centers, and clinical practices with reliable, ready-to-use sterile medications, including our specialized hormone pellets, that support seamless procedural workflows. Combined with our 503A patient-specific compounding, FarmaKeio offers a comprehensive, complementary approach that meets both individualized patient needs and the operational demands of high-volume clinical environments.